Donga Socio Holdings Posts Q2 Operating Profit of 39 Billion Won, Up 38% YoY

Revenue Jumps 19% to 412.4 Billion Won

Dong-A Socio Holdings announced on July 27 that on a consolidated basis it recorded sales of 412.4 billion won and operating profit of 39 billion won in the second quarter of this year. These figures represent increases of 18.9% and 38.3%, respectively, compared to the same period last year.

Dong-A Pharmaceutical achieved sales of 228.2 billion won, up 25.7% year-on-year, led by the growth of Bacchus and the over-the-counter pharmaceutical division. Operating profit came in at 30.2 billion won, a 26.6% increase during the same period.

By business segment, Bacchus sales grew by 26.6% to 87.8 billion won. The OTC (over-the-counter) segment recorded 74.5 billion won, up 36.5%. Sales in the HTC division, which sells health functional foods and related products, rose by 4.4% to 52 billion won.

Exterior view of Dong-A Pharmaceutical in Dongdaemun-gu, Seoul. Dong-A Socio Holdings

Dong-A Socio Holdings' biopharmaceutical contract manufacturing (CMO) subsidiary, VitiGen, underperformed as the order schedule from its major client companies was concentrated in the second half of the year. Sales dropped by 45.2% to 13.7 billion won, and operating profit decreased by 90% to 400 million won.

Yongma Logis reported sales of 120.5 billion won, backed by increased cargo volume from existing clients and the acquisition of new customers. This figure is 19.7% higher than the same period last year. Operating profit amounted to 6.9 billion won, up 41.6% year-on-year.

This content was produced with the assistance of AI translation services.